Dell'osso Bernardo, Camuri Giulia, Castellano Filippo, Vecchi Vittoria, Benedetti Matteo, Bortolussi Sara, Altamura A Carlo
Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy.
Clin Pract Epidemiol Ment Health. 2011;7:167-77. doi: 10.2174/1745017901107010167. Epub 2011 Oct 26.
Major Depression (MD) and treatment-resistant depression (TRD) are worldwide leading causes of disability and therapeutic strategies for these impairing and prevalent conditions include pharmacological augmentation strategies and brain stimulation techniques. In this perspective, repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique with a favorable profile of tolerability which, despite being recently approved by the Food and Drug Administration (FDA) for the treatment of patients with medication-refractory unipolar depression, still raises some doubts about most effective parameters of stimulation.
A literature search was performed using PubMed for the years 2001 through February 2011 in order to review meta-analytic studies assessing efficacy and safety issues for rTMS in depressive disorders. Fifteen meta-analyses were identified and critically discussed in order to provide an updated and comprehensive overview of the topic with specific emphasis on potentially optimal parameters of stimulation.
First meta-analyses on the efficacy of rTMS for the treatment of MD and TRD have shown mixed results. On the other hand, more recent meta-analytic studies seem to support the antidepressant efficacy of the technique to a greater extent, also in light of longer periods of stimulation (e.g. > 2 weeks).
rTMS seems to be an effective and safe brain stimulation technique for the treatment of medication refractory depression. Nevertheless, further studies are needed to better define specific stimulation-related issues, such as duration of treatment as well as durability of effects and predictors of response.
重度抑郁症(MD)和难治性抑郁症(TRD)是全球导致残疾的主要原因,针对这些损害性且普遍存在的病症的治疗策略包括药物增效策略和脑刺激技术。从这个角度来看,重复经颅磁刺激(rTMS)是一种非侵入性脑刺激技术,具有良好的耐受性,尽管最近已被美国食品药品监督管理局(FDA)批准用于治疗药物难治性单相抑郁症患者,但对于最有效的刺激参数仍存在一些疑问。
使用PubMed对2001年至2011年2月期间的文献进行检索,以回顾评估rTMS在抑郁症中的疗效和安全性问题的荟萃分析研究。确定并批判性地讨论了15项荟萃分析,以便对该主题提供最新且全面的概述,并特别强调潜在的最佳刺激参数。
关于rTMS治疗MD和TRD疗效的首批荟萃分析结果不一。另一方面,最近的荟萃分析研究似乎在更大程度上支持了该技术的抗抑郁疗效,尤其是考虑到更长的刺激时间(例如>2周)。
rTMS似乎是一种治疗药物难治性抑郁症的有效且安全的脑刺激技术。然而,需要进一步研究以更好地界定与刺激相关的具体问题,如治疗持续时间、疗效的持久性以及反应的预测因素。